Want to take quizzes and track your credits?
Amplification of ERBB2 (formerly referred to as HER2) is present in nearly 3% of patients with metastatic colorectal cancer overall and 5% of patients with KRAS and NRAS wild-type tumors. Despite the availability of several ERBB2-targeted therapeutic options for patients with ERBB2-positive breast and gastric/gastroesophageal tumors, to date, there are currently no approved therapies for patients with ERBB2-positive metastatic colorectal cancer, although ERBB2-targeted therapies are recommended in National Comprehensive Cancer Network guidelines. Recent evidence indicates that anti-ERBB2 therapeutic strategies are active in patients with ERBB2-positive metastatic colorectal cancer and could potentially represent a new standard-of-care.
The protein ERBB2 is a member of a family of epidermal growth factor receptors that also includes epidermal growth factor receptor (ERBB1), ERBB3, and ERBB4. Amplification of ERBB2 leads to overexpression of the ERBB2 tyrosine kinase receptor, resulting in aberrant signaling and cell migration, growth, adhesion, and differentiation. Colorectal tumors that harbor ERBB2 amplification are more likely to originate on the left side of the colon, are associated with primary and acquired resistance to anti–epidermal growth factor receptor therapies, and have increased incidence of central nervous system metastases. Using immunohistochemistry, fluorescence in situ hybridization, next-generation sequencing, and liquid biopsy techniques, several randomized clinical trials have evaluated the efficacy of ERBB2-targeted therapies in patients with ERBB2-positive metastatic colorectal cancer. These therapies include monoclonal antibodies, antibody-drug conjugates, and tyrosine kinase inhibitors, many of which were associated with favorable efficacy and safety profiles when treating patients with ERBB2-positive metastatic colorectal cancer.
Conclusions and Relevance
The results of this review suggest the ERBB2 receptor is a promising target for patients with metastatic colorectal cancer; however, to date, no therapies are approved for use in this patient population. Therefore, it is imperative to continue to work to address this unmet need so that patients with ERBB2-positive metastatic colorectal cancer have therapeutic options should they become refractory to treatment with standard therapies.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: December 14, 2021.
Published Online: March 3, 2022. doi:10.1001/jamaoncol.2021.8196
Corresponding Author: Tanios Bekaii-Saab, MD, Division of Hematology and Oncology, Mayo Clinic, 5701 E Mayo Blvd, Phoenix, AZ 85054 (email@example.com).
Author Contributions: Drs Strickler and Bekaii-Saab had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Strickler, Yoshino, Siena, Bekaii-Saab.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Strickler, Yoshino, Siena, Bekaii-Saab.
Critical revision of the manuscript for important intellectual content: All authors.
Administrative, technical, or material support: Strickler.
Supervision: Strickler, Siena, Bekaii-Saab.
Conflict of Interest Disclosures: Dr Strickler reported nonfinancial support from Seagen during the conduct of the study as well as personal fees from AbbVie, AstraZeneca, Bayer, GlaxoSmithKline, Natera, Pfizer, Seagen, Viatris, Mereo Biopharma, Silverback Therapeutics, and Inivata and grants from Bayer, Erasca, AStar D3, Silverback Therapeutics, Nektar, Roche/Genentech, Sanofi Genzyme, Gossamer Bio, AbbVie, Amgen, Daiichi-Sankyo, Curegenix, and Seagen outside the submitted work. Dr Yoshino reported grants from Taiho Pharmaceuticals, Sumitomo Dainippon Pharma, Chugai Pharmaceutical, Amgen, Sanofi, Daiichi Sankyo, Merck Sharp and Dohme, Parexel International, and ONO Pharmaceutical outside the submitted work. Dr Graham reported service on the advisory board of Incyte Advisory, personal fees from Mayo Clinic, and grants from Bristol Myers Squibb outside the submitted work. Dr Siena reported being an advisory board member for Seagen, Daiichi Sankyo, Roche-Genentech, Novartis, and Guardant during the conduct of the study. Dr Bekaii-Saab reported research funding from Agios, Arys, Arcus, Atreca, Boston Biomedical, Bayer, Amgen, Merck, Celgene, Lilly, Ipsen, Clovis, Seagen, Genentech, Novartis, Mirati, Merus, Abgenomics, Incyte, Pfizer, and Bristol Myers Squibb; consulting fees from Ipsen, Arcus, Array Biopharma, Pfizer, Seagen, Bayer, Genentech, Incyte, Merck, Stemline, AbbVie, Boehringer Ingelheim, Janssen, Eisai, Daichii Sankyo, Natera, TreosBio, Celularity, Exact Science, Sobi, Beigene, Kanaph, Xilis, AstraZeneca, and Foundation Medicine; service on independent data monitoring and data safety monitoring committees for Fibrogen, Suzhou Kintor, AstraZeneca, Exelixis, Lilly, PanCan, and 1Globe; scientific advisory board service for Imugene, Immuneering, and Sun Biopharma; and holding patents WO/2018/183488 and WO/2019/055687.
Additional Contributions: Medical writing support was provided by Sarah A. Laredo, PhD and editorial support was provided by Travis Taylor, BA, both of Scion, supported by Seagen Inc. according to Good Publication Practice guidelines (http://annals.org/aim/article/2424869/good-publication-practice-communicating-company-sponsored-medical-research-gpp3).
You currently have no searches saved.
You currently have no courses saved.